eli lilly gip/glp-1 FDA approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - New clinical trial data from

Semaglutide GLP-1 not only supports weight loss but also offers additional health benefits like lowering blood sugar, improving insulin sensitivity, reducing triglycerides, and boosting HDL cholesterol

Lower estrogen levels are associated with a redistribution of fat from the hips to the abdomen

Trends in eGFR decline and urine albumin-to-creatinine ratio (UACR) reduction are more important indicators of long-term kidney protection than changes in HbA1c or body weight (85%)

PlushCare only prescribes FDA-approved GLP1s like Ozempic, Wegovy, Mounjaro, Zepbound, and a few others

The more affordable and transparent treatment is, the more lives it has the potential to change

AstraZeneca and Bristol-Myers Squibb are a close second